Cardiff Oncology Inc’s filing revealed that its Director PACE GARY W acquired Company’s shares for reported $0.67 million on Jul 30 ’25. In the deal valued at $2.45 per share,275,000 shares were bought. As a result of this transaction, PACE GARY W now holds 1,330,676 shares worth roughly $3.34 million.
Then, PACE GARY W bought 15,000 shares, generating $36,750 in total proceeds. Upon buying the shares at $2.45, the Director now owns 1,345,676 shares.
Before that, Levine James E. bought 2,752 shares. Cardiff Oncology Inc shares valued at $14,905 were divested by the Chief Financial Officer at a price of $5.42 per share. As a result of the transaction, Levine James E. now holds 65,316 shares, worth roughly $0.16 million.
Ladenburg Thalmann initiated its Cardiff Oncology Inc [CRDF] rating to a Buy in a research note published on July 08, 2025; the price target was $19. A number of analysts have revised their coverage, including Jefferies’s analysts, who began to cover the stock in late June with a ‘”a Hold”‘ rating. Craig Hallum began covering CRDF with “Buy” recommendation on September 06, 2024. William Blair started covering the stock on January 05, 2022. It rated CRDF as “an Outperform”.
Price Performance Review of CRDF
On Monday, Cardiff Oncology Inc [NASDAQ:CRDF] saw its stock fall -4.92% to $2.51. Over the last five days, the stock has lost -32.71%. Cardiff Oncology Inc shares have risen nearly 7.26% since the year began. Nevertheless, the stocks have fallen -42.17% over the past one year.
How much short interest is there in Cardiff Oncology Inc?
A steep rise in short interest was recorded in Cardiff Oncology Inc stocks on 2025-07-15, growing by 1.61 million shares to a total of 18.9 million shares. Yahoo Finance data shows the prior-month short interest on 2025-06-13 was 17.29 million shares. There was a rise of 8.5%, which implies that there is a positive sentiment for the stock.
